Herbal extract may ease the toll of lung cancer immunotherapy

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥ 20 years * Patients who have understood and signed the informed consent. * Subjects who have been confirmed histologically and radiologically for non small cell lung cancer and are scheduled to receive treatment with immune checkpoint inhibitors * Subjects whose urine HCG are negative and who have agreed with the appropriate method of contraception in case of women of childbearing potential * Subjects who can fully communicate with their medical doctor about their symptoms or quality of life and who can fill out questionnaires * Subjects who can follow up during the clinical trial * Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2 * Hemoglobin ≥ 9g/dL Exclusion Criteria: * Subjects who are pregnant, breastfeeding, planning to become pregnant or women of childbearing potential who do not agree with the appropriate method of contraception * Subjects who have symptomatic and uncontrolled brain or central nervous system metastasis * Subjects who complain of uncontrolled pain despite using analgesics * Diastolic Blood Pressure\>100mmHg or Systolic Blood Pressure\>160mmHg * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels higher than 2.5 times the upper limit for normal * Creatinine level higher than 1.5 times the upper limit for normal * Subjects who have participated in other clinical trials within 1 months * Subjects with a history of serious drug allergies or who have hypersensitivity to the Investigational Product (the main ingredient and its components) * Subjects with autoimmune diseases * Subjects who have alcoholism or drug dependence * Subjects who have cognitive impairment or psychiatric problems * Subjects who have undergone surgery within 2 weeks * Subjects who took other herbal medicine or other medicines within 4 weeks * Subjects who have a medical condition that is likely to affect results or who are determined to be inappropriate to participate in this clinical trial at the investigator